Navigation Links
SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC
Date:8/25/2011

RINGWOOD, N.J., Aug. 25, 2011 /PRNewswire/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD; Pink Sheets: SYMD) announced that its stockholders approved the planned merger with Pathfinder, LLC at SyntheMed's special meeting of stockholders held today.  In excess of 99% of the votes cast were voted in favor of the merger.  The proposed merger with Pathfinder was previously announced and is described in detail in SyntheMed's definitive proxy statement filed with the Securities and Exchange Commission on July 26, 2011.  The merger has been approved by Pathfinder's members and is expected to close in the next ten days, subject to satisfaction or waiver of customary and other closing conditions.  

Dr. Richard Franklin, M.D., Ph.D., SyntheMed's Executive Chairman, and CEO and President of Pathfinder, commented, "I am pleased at the support shown by SyntheMed's stockholders.  Pathfinder has great potential, and I look forward to closing the merger and beginning a new direction for the Company."

About Pathfinder

Pathfinder is developing a novel cell-based therapy with the potential to revolutionize the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage. Leveraging its internal discovery of Pathfinder Cells ("PCs") and a proprietary means of isolating these cells from surrounding tissue, Pathfinder is pioneering a new field in regenerative medicine. PCs are a newly identified mammalian cell type present in very low quantities in a variety of different organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood.

Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the new tissue. The cells are "immune privileged", and their effects are independent of the tissue source of PCs. PCs isolated from both rat and human tissue sources have shown efficacy in animal models of diabetes, cardiac ischemia, and renal reperfusion injury.

For more information please visit: www.pathfindercelltherapy.com.

About SyntheMed

SyntheMed is a biomaterials company focused on the development and commercialization of anti-adhesion and drug delivery products, and other surgical implants. The Company's research and development initiatives encompass a broad range of bioresorbable polymeric compositions which blend both hydrophilic and hydrophobic components. For more information about SyntheMed please visit: www.synthemed.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements or predictions, including statements regarding the potential closing of the merger and the timing thereof, the characteristics and possible uses of the product candidates of each of Pathfinder and SyntheMed and the potential benefits or value to SyntheMed's stockholders of the merger. Actual results may differ materially from these statements.  For risks associated with the merger and Pathfinder, please see SyntheMed's definitive proxy statement filed with the SEC on July 26, 2011.  For risks associated with SyntheMed's business, please see SyntheMed's Form 10-K filed with the SEC on March 25, 2011.

For more information, please contact:

The Ruth Group
Joshua Drumm (investors) / Victoria Aguiar (media)
(646) 536-7006 / (646) 536-7013
jdrumm@theruthgroup.com / vaguiar@theruthgroup.com

Rick Franklin
Executive Chairmain, SyntheMed, Inc.
President and CEO, Pathfinder Cell Therapy, Inc.
Rick.franklin@pathfindercelltherapy.com


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016   ... the first pluripotent stem cell-derived islet replacement therapy for ... two presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, ... 22nd to 25th at Moscone West in San Francisco.  ... Details of the presentations are as follows:Event: , Focus ...
Breaking Biology Technology:
(Date:6/9/2016)... ISTANBUL , June 9, 2016  Perkotek an innovation leader in attendance control ... to seamlessly log work hours, for employers to make sure the right employees are ... Logo - http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):